

OFFICIAL**FAX COVER SHEET****PATENT**
Docket No. GC527- US
SN 09/060,872

☐ Urgent
☐ Confidential
☐ Action Required
☐ Reply Requested
☐ For Your Info.

FAX RECEIVED**TO: Art Unit 1644****MAR 7 2003****LOCATION: USPTO****GROUP 1600****Fax No.: (703) 872-9307 (After Final Facsimile No.)****FROM: Carol See for Kamrin T. MacKnight****LOCATION: GENENCOR INTERNATIONAL, INC.**
Legal Department
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7549
Fax: 650-845-6504**DATE: March 7, 2003****NUMBER OF PAGES TO FOLLOW: 10 SENT BY: cas****Re: Serial No. 09/060,872, Attorney Docket No. GC527- US****Attachments: Transmittal (1 page) in duplicate, Amendment and Response to
Final Office Action (8 pages).****The original of this facsimile will be sent to you via:**

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile _____

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone(650/846-7517) and return the original transmission to us by mail.

*attach
Paper #40*

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, After Final Facsimile No. (703) 872-9307, Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: March 7, 2003

By: *Carol A. See*

Carol A. See

PATENT
Docket No. GC527**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application:)	
)	
David A. Estell et al.)	Group Art Unit: 1644
)	
Serial No.: 09/060,872)	Examiner: Saunders, David A.
)	
Filed: April 15, 1998)	
)	
For: Mutant Proteins Having Lower Allergenic)	
Response in Humans and Methods for)	
Constructing, Identifying and Producing Such)	
Proteins)	

TRANSMITTAL LETTER

Box AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated January 7, 2003, enclosed please find the following document: Amendment and Response to Final Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: March 7, 2003

Kamrin T. MacKnight
Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-5838
Fax: 650-845-6504


GC527 AF T-OFFACT

#40/GWB

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, After Final Facsimile No. (703) 872-9307, Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: March 7, 2003

By:


Carol A. See

PATENT
Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:)	
)	
David A. Estell et al.)	Group Art Unit: 1644
)	
Serial No.: 09/060,872)	Examiner: Saunders, David A.
)	
Filed: April 15, 1998)	
)	
For: Mutant Proteins Having Lower Allergenic)	
Response in Humans and Methods for)	
Constructing, Identifying and Producing Such)	
Proteins)	

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
MAILED JANUARY 7, 2003

Box AF
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action dated January 7, 2003, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks. Applicants are submitting this Response within two months of date of the Final Office Action in order to provoke an Advisory Action.

A clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II. None of the amendments

GC527 Respm to Final